awmsg logo



sucroferric oxyhydroxide (Velphoro®)


Reference No. 1504

Publication date:
10/12/2015


Appraisal information

sucroferric oxyhydroxide (Velphoro®) 500 mg chewable tablet


Company: Vifor Fresenius Medical Care Renal Pharma UK Ltd
BNF category: Nutrition and blood
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 3315
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sucroferric oxyhydroxide (Velphoro®) is recommended as an option for restricted use within its licensed indication within NHS Wales for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Sucroferric oxyhydroxide (Velphoro®) should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease. Sucroferric oxyhydroxide (Velphoro®) should be restricted as an option for use where non-calcium based phosphate binders are considered appropriate. Sucroferric oxyhydroxide (Velphoro®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download